Medtronic plc, a leader in healthcare technology, has announced the expansion of CE Mark indications for its Prevail™ paclitaxel-coated PTCA balloon catheter. This approval allows for a broader range of treatments for coronary artery disease, including complex bifurcation lesions, multivessel disease, acute coronary syndrome, and diabetes. The expanded indications follow the Prevail DCB's strong performance in clinical trials, demonstrating low event rates and effectiveness in treating complex coronary lesions. This development enables Medtronic to better support physicians in providing top-tier care to patients with diverse and complex needs.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on May 22, 2025, and is solely responsible for the information contained therein.